Study: Khorfan FM, Smith P, Watt S, Barber KR. Effects of nebulized bronchodilator therapy on heart rate and arrhythmias in critically ill adult patients. Chest. 2011 Dec;140(6):1466-72.
Methods: This was a 2:1 randomized, prospective, single-blind crossover study in 70 adult ICU patients who were randomized to alternating 4-6 hour courses of nebulized albuterol (2.5 mg) or levalbuterol, along with ipratropium. Group A received 0.63 mg, while Group B received 1.25 mg of levalbeterol. Cardiac monitoring was performed to measure heart rate and rhythm before, during and after treatment.
Results: The 70 patients consisted of almost equal numbers of men and women, with age ranges from 35-92, and slightly more than half on mechanical ventilation. Multisystem organ problems were common in this population. The median number of treatments per patient was 23, ranging from 1 to 45. There was no significant difference in change in heart rate after albuterol (0.89 ± 4.5 bpm) or levalbuterol (0.85 ± 5.3 bpm) treatment in Group A. In Group B, levalbuterol actually was associated with faster heart rate (increase of 1.4 ± 5.4 bpm) compared to albuterol (decrease of 0.16 ± 5.1 bpm) (p=0.03); but when analyzing for measures that were taken >= 5 hours apart, this difference was no long statistically significant. There was only one patient who had to be discontinued on treatment, after experience a 5 beat run of NSVT after 6x albuterol treatment.
Discussion: As for levalbuterol, its substitution for albuterol was not justified in this study - in fact, in Group B, in which a higher levalbuterol dose was used, post-therapy heart rate was actually faster than post-albuterol heart rate. Unexpectedly, from this study, it seemed that albuterol or levalbuterol did not significantly worsen tachycardia, even in this very sick population of patients. This is useful - and comforting - to know for patients who are tachycardic, but also have wheezes or increased airway resistance who would benefit from temporary courses of nebulized beta-agonists. One limitation of the applicability of this study is the fact that heart rate comparisons were made only after a limited number of treatments per patient, so it could be possible that over longer term and more treatments +/- higher frequency +/- higher dosing, there would be significantly increased heart rate. So in a patient receiving longer term albuterol therapy, I would still consider tapering down or decreasing albuterol therapy if tachycardia were a problem, since this would make sense physiologically.